Full-Time

Corporate Compliance Officer

Capricor Therapeutics

Capricor Therapeutics

201-500 employees

Biotech developing cell- and exosome therapeutics

Compensation Overview

$210k - $270k/yr

San Diego, CA, USA

In Person

Category
Legal & Compliance (2)
,
Required Skills
FDA Regulations
Requirements
  • Bachelor’s degree required; J.D. preferred.
  • 10+ years of progressive compliance experience in the pharmaceutical or biotechnology industry, with at least 5 years in a leadership role overseeing compliance programs.
  • Demonstrated experience managing international trade compliance matters involving Europe and/or Japan (export controls, sanctions, customs, technology transfer, or equivalent).
  • Deep knowledge of compliance laws and industry codes.
  • Experience supporting commercialization and launch-stage activities in biotech/pharma strongly preferred.
  • Proven ability to build and lead compliance functions in dynamic, fast-paced environments.
  • Strong risk assessment, investigation, and issue-management skills.
  • Excellent communication, influence, and cross-functional collaboration abilities.
Responsibilities
  • Compliance Program Leadership & Governance: Design, implement, maintain, and continuously improve Capricor’s corporate compliance program, including policies, procedures, risk assessments, monitoring, and auditing frameworks.
  • Assist in the development, implementation, and updating of corporate policies, SOPs, and legal processes.
  • Lead the development and delivery of compliance training and communications across the organization.
  • Oversee compliance monitoring, internal investigations, corrective actions, and reporting to senior leadership and the Board as needed.
  • Maintain and enhance compliance tools, playbooks, dashboards, and processes to support scalability.
  • Commercialization Readiness: Provide strategic compliance guidance on commercialization planning, including distribution, supply chain, marketing, field operations, patient support programs, and HCP/payer engagements.
  • Ensure promotional materials, scientific exchange, pre-approval communications, medical affairs activities, and vendor interactions comply with FDA, EMA, Sunshine Act, Anti-Kickback Statute, False Claims Act, and other relevant laws.
  • Review commercial, medical, and vendor-related materials and activities for regulatory and compliance risk.
  • International Trade Compliance (Europe and/or Japan): Oversee compliance with U.S. and foreign export controls, sanctions regimes (OFAC, EU, Japan), customs regulations, and trade agreements relevant to Capricor’s operations and partnerships in Europe and/or Japan.
  • Manage classification, licensing, and documentation for cross-border transfers of technology, biological materials, data, and equipment.
  • Conduct due diligence and risk assessments for international transactions, partnerships, and clinical/commercial activities in these regions.
  • Third-Party & Vendor Compliance Oversight: Lead third-party risk management, including anti-corruption due diligence (FCPA/UK Bribery Act/Japanese regulations), screening, contracting requirements, and ongoing monitoring.
  • Collaborate with Procurement, CMC, Manufacturing, Quality, and International teams to ensure third-party obligations meet compliance and operational standards.
  • Address vendor compliance issues, disputes, and audit findings.
  • Corporate, Operational & Risk Support: Partner on data privacy (GDPR, CCPA, etc.), confidentiality, information governance, and cybersecurity compliance initiatives.
  • Support audit readiness, regulatory inspections, and third-party assessments.
  • Advise on emerging regulatory and compliance trends in pharma/biotech and communicate implications to stakeholders.
Capricor Therapeutics

Capricor Therapeutics

View

Capricor Therapeutics develops cell- and exosome-based therapies to treat serious diseases. Its products use cells or tiny vesicles released by cells to repair heart tissue, Duchenne muscular dystrophy, and COVID-19–related complications, and are advanced through research and clinical trials before potential commercialization. It differentiates itself by focusing on cell- and exosome-based approaches rather than small molecules, pursuing a portfolio aimed at high-need conditions. The company’s goal is to improve patient outcomes by validating these therapies and bringing them to hospitals and healthcare providers, supported by partnerships and grants.

Company Size

201-500

Company Stage

IPO

Headquarters

Beverly Hills, California

Founded

2005

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approval expected August 22, 2026 enables rapid market entry and revenue generation.
  • Manufacturing facility passed FDA pre-license inspection; capacity scales to 2,500 patients annually.
  • $318 million cash runway funds operations through Q4 2027 post-launch commercialization.

What critics are saying

  • FDA rejects Deramiocel BLA again by August 22, 2026 due to manufacturing deficiencies.
  • Sarepta's Elevidys gene therapy captures 80% DMD market share within 24 months.
  • EVP insider share sales signal management doubts; stock drops 50% pre-approval decision.

What makes Capricor Therapeutics unique

  • First therapy delivering statistically significant upper limb function improvement in DMD.
  • Rare Pediatric Disease Designation qualifies Capricor for valuable Priority Review Voucher.
  • Exclusive US and Japan commercialization partnership with Nippon Shinyaku validates market potential.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Capricor Therapeutics who can refer or advise you

Benefits

Health Insurance

401(k) Retirement Plan

Remote Work Options

Unlimited Paid Time Off

Flexible Work Hours

Paid Vacation

Staff Training (not in predefined)

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

2%

2 year growth

-3%
Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces $23 Million Registered Direct Offering

SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces Closing of $5.1 Million Offering Priced At-the-Market

LOS ANGELES, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Provides Corporate Update and Reports First Quarter 2016 Financial Results

HOPE-Duchenne and ALLSTAR Clinical Trials on Track to Complete Enrollment in the Third Quarter Company to Host Conference Call and Webcast at 4:30…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces $7 Million Private Placement of Common Stock

Institutional Investors Include: Broadfin Capital, LLC and Sabby Capital, LLC LOS ANGELES, Feb. 4, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics,…...